Post-marketing Surveillance of Spesolimab I.V. Infusion in Improvement of Generalized Pustular Psoriasis (GPP) With Acute Symptoms in Japan
Latest Information Update: 10 Feb 2026
At a glance
- Drugs Spesolimab (Primary)
- Indications Generalised pustular psoriasis
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
Most Recent Events
- 23 Jan 2026 According to LEO Pharma media release, data from the trial will be presented at Maui Derm Hawaii 2026.
- 20 Oct 2025 Status changed from active, no longer recruiting to completed.
- 13 Mar 2025 Status changed from recruiting to active, no longer recruiting.